Holzkirchen, Germany, January 14, 2014 – Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December …
Holzkirchen, Germany, January 13, 2014 – Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December 1…
Januar 08, 2014 – Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs.Learn more (PDF 743 KB)
Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the USBiosimilar filgrastim recommended to be approved for use in all requested indicationsCommittee’s recommendation based on review of exte…
Munich, December 18, 2013 – Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval…